Abcam (NASDAQ:ABCM) Shares Gap Up to $16.82

Posted by on Jun 12th, 2023

Abcam plc (NASDAQ:ABCM – Get Rating) shares gapped up before the market opened on Monday . The stock had previously closed at $16.82, but opened at $17.26. Abcam shares last traded at $17.58, with a volume of 495,045 shares.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada boosted their target price on Abcam from $21.50 to $23.00 in a research report on Friday, April 28th.

Abcam Stock Performance

The business has a 50 day moving average of $16.01 and a 200 day moving average of $15.47.

Institutional Trading of Abcam

A number of large investors have recently made changes to their positions in ABCM. 1832 Asset Management L.P. acquired a new stake in shares of Abcam during the first quarter valued at $32,000. Belpointe Asset Management LLC boosted its stake in shares of Abcam by 72.0% during the first quarter. Belpointe Asset Management LLC now owns 2,568 shares of the company’s stock valued at $35,000 after acquiring an additional 1,075 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Abcam by 820.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 2,898 shares of the company’s stock valued at $39,000 after acquiring an additional 2,583 shares during the last quarter. Van ECK Associates Corp boosted its stake in shares of Abcam by 41.4% during the fourth quarter. Van ECK Associates Corp now owns 3,536 shares of the company’s stock valued at $55,000 after acquiring an additional 1,035 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Abcam by 48.7% during the first quarter. JPMorgan Chase & Co. now owns 3,044 shares of the company’s stock worth $56,000 after buying an additional 997 shares during the period. Institutional investors and hedge funds own 13.91% of the company’s stock.

Abcam Company Profile

(Get Rating)

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.

Read More

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.